Similarly, further studies are needed to determine the frequency of ER+ tumors that are negative for both PR and CAXII (one tumor in our cohort, positive for FOXA1 and GATA3), and whether these tumors are also negative for other ER target genes and are unresponsive to hormonal therapies. This evidence concerns the gene FOXA1 and neoplasm.